Inspire Pharmaceuticals, Inc.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has submitted a clinical protocol and request for Special Protocol Assessment (SPA) to the U.S.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the standard 30-day review period by the U.S.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today publication of two papers related to the denufosol for cystic fibrosis development program in peer-reviewed journals. The first paper, "Denufosol: A Review of Studies with Inhaled P2Y2 Agonists that led to Phase 3" (D. Kellerman, A.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced modifications to the clinical protocol for TIGER-2, the Company's ongoing second Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis (CF).